12,372 trials
Neisseria Meningitidis · Bacterial Infections · Virus Diseases
Primary: Percentage of Participants With an Anti-Hepatitis B Surface Antigen (HBsAg) Antibody Titer ≥10 mIU/mL — 98.9 Percentage of Participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 30 — -1.88; -1.42 Percent A1C — p=< 0.001
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 — 50.7; 60.9; 65.0 percentage of participants — p=0.005
Non-Small Cell Lung Cancer
Primary: Median Overall Survival — 11.99; 9.63 Months — p=0.0006
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United…
Palmoplantar Pustulosis
Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001
Gastroenteritis · Gastritis
Primary: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population — 126; 70; 12; 5 Participants — p=0.0406
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach) — 120; 47; 60; -45 mL
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696…
Tooth Erosion
Primary: % Surface Micro Hardness Recovery (SMHR; Comparison of 1150 Ppm Fluoride and 5% KNO3 Dentifrice Relative to a Fluoride Free Placebo Dentifrice to Enhance…
Congenital Fibrinogen Deficiency
Primary: Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in Treating the First Documented Bleeding Episode of Each Patient. — 19; 23; 5; 1 Participants
Spinal Metastases
Primary: Local Tumor Control Using MRI or CT
Psoriasis · Plaque Type Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 — 89.7; 91.6 Percentage of Participants
HIV-1 Infection
Primary: Percent Change From Baseline to Week 48 in Spine BMD — 2.237; -0.104 Percent change — p=<0.001
Anesthesia, General
Primary: Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9. — 1.62; 26.78; 4.47; 23.43 Minutes